Log in

Industry News

FDA Approvees Fam-Trastuzumab Deruxtecan-nxki for HER2-Mutant NSCLC

On August 11, 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to fam-trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating human epidermal growth factor receptor 2 HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.

For more information, read the FDA announcement or the AstraZeneca and Daiichi Sankyo announcement.

Posted 8/15/2022

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us